Search Results

We sat down to chat about GPCRs, synthesizing labeled ligands, and her unique position that allows her

Peter Gmeiner has been spokesman of the Research Training Group "Medicinal Chemistry of Selective GPCR Ligands

🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! 🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

protein-coupled receptors using innovative approaches, including biosensors, cryo-EM, photoswitchable ligands

His research interest lies in understanding the molecular basis for human tumor development and how to Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic molecules and is currently developing novel small molecule inhibitors of the hypoxia-inducible factor His research aims to translate these novel agents to testing in clinical trials with the hope to develop the future, we plan to decipher the roles of N-glycosylation of ADGRG6 in organogenesis and tissue development

research focuses on class B GPCRs and understanding how GPCR signaling and function is mediated by various ligands

I study the cell and tissue level consequences of its failure in foetal development and of its reemployment were born at predicted Mendelian frequencies, appeared grossly indistinguishable from Con mice, and developed Since staring my postdoctoral training, I have continued to develop my expertise to answer fundamental Mariam Melkumyan Abstract "GPR110, an adhesion G protein coupled receptor (GPCR), is widely expressed in developing Ligand-induced GPR110 signaling stimulates neurogenesis and synaptogenesis during development, and the

This project aims to characterise the molecular pharmacology of GPR146 and to validate the proposed ligands

used radioligand binding methods to dissect receptor function from the adenylyl cyclase activated by ligands

regulating renal and cardiovascular function, and identifying renal/cardiovascular olfactory receptor ligands

Computational Biochemistry at Uppsala University , where his lab uses structure-based modeling to predict GPCR-ligand

He primarily studies the chemokine receptor CXCR3 as it has three naturally occurring ligands and thus

receptor kinetics, signaling, and trafficking and on using novel imaging techniques, such as fluorescent ligands

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

Broichhagen reveals how fluorescent probes transform GPCR imaging, internalization studies, and assay development Why peptide-based fluorescent ligands succeeded where antibodies repeatedly failed. Balanced creativity in tool development with the pressure for reproducible, publication-grade data. research group at the Leibniz Research Institute for Molecular Pharmacology (FMP) in Berlin, focusing on developing

In particular, FB contributed to the discovery that CXCL12 is the ligand for the CXCR4 receptor and can

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

GPCR Title: Development of a Transgenic Mouse Platform for the Detection of Endogenous G protein Activity protein engineering, receptor pharmacology, and structural biology to study how different types of ligands

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand

biased agonism, and also on allosteric interactions between GPCRs and other proteins and small molecule ligands

best leverage these exciting new techniques in areas such as protein structure prediction, bioactive ligand

empowers scientists to simplify complex workflows, accelerate discovery, and drive breakthroughs in drug development He currently leads Revvity's Research and Development activities, focusing on biochemical and cellular Before joining Revvity, Eric worked for Cisbio Bioassays first as Director of Technological Development department, leading her team on the development of innovative HTRF™ and AlphaLISA™ kits for pharma, Eric Trinquet, Director of Research and Development at Revvity.